



INVESTOR IN PEOPLE

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

EP/04/11958


I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

I also certify that the application is now proceeding in the name as identified herein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed *Andrew Gersey*  
Dated 10 February 2005


BEST AVAILABLE COPY



GB0326416.5

By virtue of a direction given under Section 30 of the Patents Act 1977, the application is proceeding in the name of:-

NEWCO 1378 SWEDEN AB UNDER NAME CHANGE TO PREDICTOR AB  
Incorporated in Sweden  
Karolinska Innovations AB  
Fogdevreten 2b  
S-171 77 Stockholm  
Sweden  
ADP No. 08957920001



# Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office if you fill in this form)

The Patent Office

Cardiff Road  
Newport  
South Wales

1. Your reference	NRS/FP6191019			0326416.5
2. Patent application number (The Patent Office will fill this part in)	12 NOV 2003	13NOV03 E851702-1 D00060	P01/7700 0.00-0326416.5	
3. Full name, address and postcode of the or of each applicant (underline all surnames)	KAROLINSKA INNOVATIONS AB FOGDEVRETEN 2b S-171 77 Stockholm SWEDEN			
Patents ADP number (if you know it)	SECTION 39(1977 ACT) APPLICATION FILED 21-09-04			
If the applicant is a corporate body, give the country/state of its incorporation	8471047001 SWEDEN			
4. Title of the invention	Methods and Means Relating to Hepatitis B Infection.			
5. Name of your agent (if you have one)	"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode) MEWBURN ELLIS York House 23 Kingsway London WC2B 6HP			
Patents ADP number (if you know it)	109006			
6. Priority: Complete this section if you are declaring priority from one or more earlier patent applications, filed in the last 12 months.	Country	Priority application number (if you know it)	Date of filing (day / month / year)	
7. Divisionals, etc: Complete this section only if this application is a divisional application or resulted from an entitlement dispute (see note f)	Number of earlier UK application		Date of filing (day / month / year)	
8. Is a Patents Form 7/77 (Statement of inventorship and of right to grant of a patent) required in support of this request?	YES			
Answer YES if: a) any applicant named in part 3 is not an inventor, or b) there is an inventor who is not named as an applicant, or c) any named applicant is a corporate body. Otherwise answer NO (See note d)				

9. Accompanying documents: A patent application must include a description of the invention. Not counting duplicates, please enter the number of pages of each item accompanying this form:

Continuation sheets of this form

Description	35
Claim(s)	3
Abstract	1
Drawing(s)	22 + 22

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for a preliminary examination and search (Patents Form 9/77)

1

Request for a substantive examination (Patents Form 10/77)

Any other documents (please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature(s)

N Sutcliffe

Date 10 November 2003

12. Name, daytime telephone number and e-mail address, if any, of person to contact in the United Kingdom

Nicholas R Sutcliffe

020 7240 4405

### Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

### Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered YES in part 8, a Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- Part 7 should only be completed when a divisional application is being made under section 15(4), or when an application is being made under section 8(3), 12(6) or 37(4) following an entitlement dispute. By completing part 7 you are requesting that this application takes the same filing date as an earlier UK application. If you want the new application to have the same priority date(s) as the earlier UK application, you should also complete part 6 with the priority details.

Methods and Means Relating to Hepatitis B Infection.

This invention relates to the use of interferon (IFN) to treat hepatitis B (HBV) infection and, in particular, to the identification of HBV patients for whom IFN treatment is likely to be beneficial.

Hepatitis B infection is associated with high morbidity and mortality (Niederau C. et al (1996) *The New England Journal of Medicine* 334, 1422-1427). HBV infection is associated with cirrhosis, liver failure, hepatocellular carcinoma and death (Dudley FJ et al (1972) *Lancet* ii: 1388-1393; Hoofnagle JH et al (1983) Chronic type B hepatitis: Clinical course. In: *Viral Hepatitis and Delta Infection*. New York; Alan R Liss Inc, 1983; 41-53; Weissberg J et al (1984) *Annal Internal Medicine* 101: 613-616.; Fattovich G. et al (1986) *Hepatology* 6: 167-172; Popper H et al (1987) *Hepatology* 7: 764-772).

Several randomized clinical trials have reported that therapy with recombinant interferon alpha (IFN-alpha) offers significant clinical benefits. The rate of elimination of hepatitis B e antigen (HBeAg) increased with IFN treatment from a low rate of spontaneous clearance of 5-10 percent to approximately 24-30 percent (Hoofnagle JH et al (1988) *Gastroenterology* 95: 1318-1325.; Alexander GJM et al (1987) *Lancet* 2: 66-69; Brook MG et al (1989) *Gut*: 130: 1116-1122; Saracco G et al (1989) *Hepatology* 10: 336-341.; Perillo RP et al (1990) *New England Journal of Medicine* 323: 295-301.; Tine F et al (1993) *Journal of Hepatology* 18: 154-162; Cooksley WGE et al (2003) *Journal of Viral Hepatitis* 10: 298-305). The interferon-induced elimination of hepatitis e antigen

is accompanied of a reduced incidence of hepatocellular carcinoma (Yang H-I et al (2002) *The New England Journal of Medicine* 347: 168-174).

- 5 Given the side-effects associated with IFN treatment, the ability to identify those patients who are likely to respond to interferon therapy would be useful in making recommendations for treatment (Lau DT-Y et al (1998) *Journal of Viral Hepatitis* 5: 105-114).

10

- A range of markers have been proposed for use in predicting whether a patient will respond to interferon treatment, including serum levels of transaminases, HBV-DNA, HBeAg, HBV preS1 antigen and IgM antibodies to HBeAg or HBeAg. (Krogsgaard et al, 1994 *Journal of hepatology* 21: 646-655; Brook et al, 1989b *Hepatology* 10: 761-763; Perillo et al, 1988 supra; Dienstag et al, 1995, *New Journal England Medicine* 333: 1657-1661; Villeneuve et al, 1996 *Cancer Journal Gastroenterology* 10: 21-25; 15 Janssen et al, 1999 *Hepatology* 30: 238-243; Brunetto et al, 1993 *Journal of Hepatology* 19: 431-436; Marinos et al, 1994 *Hepatology* 19: 303-311).
- 20

- PreS1 antigen (PreS1 Ag) is detectable in serum during 25 HBV- infection and has been suggested to be a reliable marker for monitoring residual HBV replication in chronically infected patients receiving antiviral therapy as well a predictor of IFN response (Petit MA et al (1990) *Hepatology* 11: 809-814; Petit MA et al (1992a) 30 *Archives of Virology Suppl* 4: 105-112; Petit MA et al (1992b) *Virology* 187: 211-222; Petit MA et al (1994) *Journal of Hepatology* 20: 47-56; Feng et al, 1995 *Zhonghua Yixue Jianyan Zazhi* 18: 154-157; Ibarra et al, 1989 *Liver* 9: 153-158; Mi et al, 1999 *Chinese Medical*

*Journal* 112: 321-324; Buffello-Le Guillou et al, 2000  
*Journal of Viral Hepatitis* 7: 387-392).

A synthetic peptide analogue (preS1# 21-47) of a portion  
 5 of the preS1 antigen is recognized by both cell receptors  
 and anti-HBV antibodies. Furthermore, this peptide  
 elicits antibodies reacting with native HBV. Among the  
 preS1-specific peptides 1-21, 12-32, 32-53 and 94-117,  
 only the peptide 12-32 is recognized strongly by human  
 10 anti-HBV (Neurath et al, 1986 *Cell* 46: 429-436; Neurath  
 AR (1988a) *Advances Virus Research* 34: 65-142; Neurath  
 AR (1988b) *Ann.Inst.Pasteur/Virol* 139: 13-38).

Serum antibodies with specificity for preS1 antigen have  
 15 been demonstrated early in acute HBV- infection (Alberti  
 et al, 1978 *British Medical Journal* 14: 1056-1058;  
 Theilmann et al, 1986 *Hepatology* 6: 186-190; Hellström  
 and Sylvan, 1988 *Progress in Medical Virology* 35: 76-  
 106; Budowska et al (1990) *Hepatology* 12: 1271-1277;  
 20 Budowska et al (1992) *Hepatology* 15: 26-32). 22.7%  
 (15/66) patients with chronic hepatitis B were positive  
 for antibody to the C- terminus (94-117) preS1 sequence  
 that, unlike the acute-phase anti-(21-32) and anti-(32-  
 47) reactivities, did not behave as a virus-  
 25 precipitating antibody. More than half of 19 acute  
 hepatitis B patients produced anti-preS1(21-119)  
 antibodies, during recovery of the disease, however, the  
 response was found only in a few chronic patients (Wei et  
 al (2002) *World Journal of Gastroenterology* 8: 276-281).

30 The present inventors have discovered that the presence  
 of antibodies reactive with a specific portion of the  
 PreS1 component of the hepatitis B surface antigen  
 (HBsAg) antigen in a sample from an individual with HBV

infection correlates closely with the effectiveness of interferon (IFN) in treating the individual.

One aspect of the invention provides a method of  
5 predicting whether an individual infected with hepatitis B virus (HBV) will respond to interferon (IFN) treatment, the method comprising;

determining the presence or amount of antibodies  
reactive with a preS1(94-117) peptide in a sample  
10 obtained from the individual.

The presence of antibodies reactive with a preS1(94-117)  
peptide in the sample is indicative that the individual  
is a responder for whom the treatment will be beneficial  
15 (i.e. someone who will respond to IFN treatment).

An individual who is responsive to IFN treatment (i.e. a responder) may, in response to IFN treatment, show an improvement in one or more symptoms of HBV infection. For  
20 example, the level of one or more biomarkers associated with HBV infection, such as serum HBeAg levels, may be reduced or eliminated by IFN treatment of an individual who is responsive to the treatment.

25 A method as described herein may be used to determine whether or not an individual having hepatitis B virus (HBV) infection is a responder to interferon (IFN) treatment. A method may thus comprise identifying an individual having antibodies reactive with said peptide  
30 as a responder to IFN treatment.

An individual suitable for analysis using the present methods may have a chronic or an acute hepatitis B infection. The individual may show one or more symptoms



of HBV infection, for example, the individual may be HBeAg positive.

An antibody reactive with a preS1(94-117) peptide is an antibody molecule which binds or reacts with a preS1(94-117) peptide.

In some embodiments, an antibody reactive with an antigen such as a preS1(94-117) peptide may not show any significant binding to molecules other than the antigen (i.e. it may show specific binding). In some cases, an antibody may specifically bind to a particular epitope, such as the preS1(94-117) epitope, which is carried by a number of antigens, in which case the antibody will be able to bind to the various antigens carrying the epitope. Thus, antibodies to the preS1(94-117) epitope may also bind to other peptides and polypeptides comprising the preS1(94-117) epitope, such as preS1 antigen.

An antibody molecule reactive with preS1(94-117) whose presence is determined in accordance with the methods described herein, may be any immunoglobulin molecule which is produced by the immune system of the individual in response to a foreign antigen, for example IgG, IgD, IgM, IgA or IgE. In preferred embodiments, an IgG molecule is detected.

A preS1(94-117) peptide may consist of residues 94 to 117 of the HBV preS1 sequence. The HBV preS1 sequence may be from any subtype of HBV, including for example subtypes ayw, adyw, adw, adw<sub>2</sub> or adr. Peptide sequences of preS1 are described in Neurath AR, Kent SB (1988) *Advances*

*Virus Research* 34: 65-142 and Neurath AR et al (1988)  
*Ann.Inst.Pasteur/Virol* 139: 13-38.

In some preferred embodiments, a preS1(94-117) peptide  
 5 may have the following amino acid sequence;

PX<sub>1</sub>STNRQSGRQPTPX<sub>2</sub>SPPLRX<sub>3</sub>X<sub>4</sub>HP

where X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub> and X<sub>4</sub> may be any amino acid.

Preferably, X<sub>1</sub> is independently A or V.

10 Preferably, X<sub>2</sub> is independently L or I.

Preferably, X<sub>3</sub> is independently D, N or T,

Preferably, X<sub>4</sub> is independently T or S.

In some especially preferred embodiments, a preS1(94-117)  
 15 peptide may have one of the following sequences (X<sub>1</sub>, X<sub>2</sub>  
 and X<sub>3</sub> shown in bold);

(i) PASTNRQSGRQPTPLSPPLRNTHP

(ii) PASTNRQSGRQPTPLSPPLRTTHP

(iii) PASTNRQSGRQPTPISPLRDSHP

20

Sequences of preS1(94-117) from other HBV sub-types may  
 be identified using conventional sequence analysis of  
 public databases.

25 The presence of an antibody reactive with a preS1(94-117)  
 peptide may be determined by any convenient means and  
 many suitable techniques are known in the art. For  
 example, the sample may be contacted with a polypeptide  
 comprising or consisting of a preS1(94-117) epitope.

30 Binding of antibody molecules in the sample to the  
 preS1(94-117) epitope of the polypeptide may then be  
 determined, for example, by measuring immunocomplex  
 formation between the preS1(94-117) peptide and  
 antibodies in the sample.

Binding of antibody molecules may be determined by any appropriate means. Tagging with individual reporter molecules is one possibility. The reporter molecules may

5 directly or indirectly generate detectable, and preferably measurable, signals. The linkage of reporter molecules may be direct or indirect, covalent, e.g. via a peptide bond, or non-covalent. Linkage via a peptide bond may be as a result of recombinant expression of a  
10 gene fusion, encoding antibody and reporter molecule. For example, an antibody or preS1(94-117) peptide may be labelled with a fluorophore such as FITC or rhodamine, a radioisotope, or a non-isotopic-labelling reagent such as biotin or digoxigenin; antibodies containing biotin may  
15 be detected using "detection reagents" such as avidin conjugated to any desirable label such as a fluorochrome. Another possibility is to detect the binding of antibodies to the preS1(94-117) antigen using a second antibody, for example in an ELISA assay system. The  
20 second antibody may, for example, be a non-human antibody that binds to human antibodies. Depending on the assay format employed, the second antibody may be immobilised or labelled with a detectable label.

25 In some embodiments, a labelled third antibody may be used to detect the binding of the second antibody.

The mode of determining binding is not a feature of the present invention and those skilled in the art are able  
30 to choose a suitable mode according to their preference and general knowledge.

Suitable approaches for determining the presence of antibodies as described above include Western Blotting,

immunofluorescence, enzyme linked immunosorbent assays (ELISA), radioimmunoassays (RIA), immunoradiometric assays (IRMA) and immunoenzymatic assays (IEMA), including sandwich assays using monoclonal and/or polyclonal antibodies. All of these approaches are well known in the art.

A preS1(94-117) peptide as described above for use in methods of the invention may be generated wholly or partly by chemical synthesis or by recombinant expression from encoding nucleic acid.

PreS1(94-117) peptides may be readily prepared according to well-established, standard liquid or, preferably, solid-phase peptide synthesis methods, general descriptions of which are broadly available (see, for example, in J.M. Stewart and J.D. Young, Solid Phase Peptide Synthesis, 2nd edition, Pierce Chemical Company, Rockford, Illinois (1984), in M. Bodanzsky and A. Bodanzsky, The Practice of Peptide Synthesis, Springer Verlag, New York (1984); and Applied Biosystems 430A Users Manual, ABI Inc., Foster City, California), or they may be prepared in solution, by the liquid phase method or by any combination of solid-phase, liquid phase and solution chemistry, e.g. by first completing the respective peptide portion and then, if desired and appropriate, after removal of any protecting groups being present, by introduction of the residue X by reaction of the respective carbonic or sulfonic acid or a reactive derivative thereof.

A peptide may be made resistant to proteolysis by the replacement of a -CONH- peptide bond by a (CH<sub>2</sub>NH) reduced bond, a (NHCO) retro inverso bond, a (CH<sub>2</sub>-O) methylene-oxy

bond, a (CH<sub>2</sub>S) thiomethylene bond, a (CH<sub>2</sub>CH<sub>2</sub>) carbon bond, a (CO-CH<sub>2</sub>) cetomethylene bond, a (CH<sub>2</sub>H-CH<sub>2</sub>) hydroxyethylene bond), a (N-N) bound, a E-alcene bond or a CH=CH-bond.

5

Peptides may also be conveniently produced by expressing encoding nucleic acid in a recombinant expression system and isolating and/or purifying the expressed peptide. Suitable techniques for such expression are well known in the art.

10

A preS1(94-117) peptide or polypeptide comprising a preS1(94-117) epitope for use in a method described herein may be immobilised or non-immobilised i.e. free in solution.

15

A peptide may be immobilised, for example, by attachment to a solid support for use in an immunoassay. The support may be in particulate or solid form and may include a plate, a test tube, beads, a ball, a filter or a membrane. A peptide may, for example, be fixed to an insoluble support that is suitable for use in affinity chromatography. Methods for fixing peptides to insoluble supports are known to those skilled in the art. An immobilised peptide may be preferred, for example, in assay formats such as ELISA.

20

25

A solid support may be any material that is an insoluble matrix and can have a rigid or semi-rigid surface. Exemplary solid supports include, but are not limited to, substrates such as nitrocellulose (e.g., in membrane or microtiter well form); polyvinylchloride (e.g., sheets or microtiter wells); polystyrene latex (e.g., beads or microtiter plates); polyvinylidene

30

fluoride; diazotized paper; nylon membranes; activated beads, magnetically responsive beads, and the like. Particular supports include plates, pellets, disks, capillaries, hollow fibers, needles, pins, solid fibers, 5 cellulose beads, pore-glass beads, silica gels, polystyrene beads optionally cross-linked with divinylbenzene, grafted co-poly beads, polyacrylamide beads, latex beads, dimethylacrylamide beads optionally crosslinked with N-N'-bis-acryloylethylenediamine, and 10 glass particles coated with a hydrophobic polymer.

If desired, the molecules to be added to the solid support can readily be functionalized to create styrene or acrylate moieties, thus enabling the incorporation of 15 the molecules into polystyrene, polyacrylate or other polymers such as polyimide, polyacrylamide, polyethylene, polyvinyl, polydiacetylene, polyphenylene-vinylene, polypeptide, polysaccharide, polysulfone, polypyrrole, polyimidazole, polythiophene, polyether, epoxies, silica 20 glass, silica gel, siloxane, polyphosphate, hydrogel, agarose, cellulose, and the like.

Another aspect of the invention provides an immunoassay solid support comprising a preS1(94-117) peptide. 25

Preferred immunoassay solid supports are described above and include microtiter plates.

An immunoassay solid support may be produced by a method 30 comprising:

- (a) providing a solid support; and
- (b) binding a preS1(94-117) peptide to said support..

Techniques for binding peptides to a solid support are well-known in the art and are described in more detail above.

- 5 An immunoassay solid support may be useful in performing a method of the invention. A method of predicting whether an individual having hepatitis B virus (HBV) infection will respond to interferon (IFN) treatment, may comprise:
- 10 (a) providing an immunoassay solid support comprising a preS1(94-117) peptide,
- (b) combining a biological sample with said solid support under conditions which allow antibodies reactive with said peptide, when present in the biological sample, to bind to said peptide, and;
- 15 (c) detecting and/or measuring complexes formed between said antibodies and said peptide.

Complexes may be detected as described above by adding to the solid support from step (b), under complex forming

20 conditions, a second antibody, wherein said second antibody binds to antibodies from said sample. For example, the second antibody may be an anti-IgG antibody. The second antibody may be detectably labelled.

- 25 For example, the methods described herein may be performed in an ELISA format. The wells of a microtiter plate may be coated with the peptide and a biological sample containing or suspected of containing antibody molecules is then added to the coated wells. After a
- 30 period of incubation sufficient to allow antibody binding to the immobilized solid-phase peptide, the plate(s) can be washed to remove unbound moieties and a detectably labelled secondary binding molecule (e.g. labeled anti-IgG antibody) added. These molecules are

allowed to react with any captured antibody bound to the peptide, the plate washed and the presence of the labeled antibodies detected using methods well known in the art.

5 Another aspect of the invention provides a kit for use in predicting whether an individual having hepatitis B will respond to interferon (IFN) treatment, the kit comprising a preS1(94-117) peptide.

10 The peptide may be immobilised on a solid support, for example, a microtitre plate.

The kit may include instructions for use in a method for determining the presence of the antibodies of interest in  
15 a test sample. A kit may include one or more other reagents required for the method, such as secondary antibodies, detection reagents, buffer solutions etc.

The secondary antibody may be labelled. A kit for use in determining the presence or absence of antibody of  
20 interest may include one or more articles and/or reagents for performance of the method, such as means for providing the test sample itself, e.g. a syringe for removing a sample and sample handling containers (such components generally being sterile).

25

Another aspect of the invention provides a method of treating an individual having hepatitis B comprising;  
identifying the individual as responsive to  
interferon (IFN) treatment using a method as described  
30 herein, and;

administering IFN to said individual.

The IFN may be IFN-alpha, for example IFN-alpha 2a/2b or  
pegIFN-alpha 2a/2b, preferably IFN-alpha 2a or pegIFN-



alpha 2a (Cooksley et al (2003) *J Viral Hepatitis* 10: 298-305, Manns et al (2001) *Lancet* 358:958-965).

IFN-alpha may be administered under the supervision of a  
5 medical practitioner in accordance with standard  
practice. For example, dosages of interferon-alpha of 2.5  
to 5 million units (MU) per meter square (/MSq) of body  
surface area three times a week are commonly employed.  
Higher doses (up to 10MU/MSq) of interferon may also be  
10 used and some studies indicate that higher doses have an  
improved response rate. Alternatively, 5 million units  
may be administered daily. IFN-alpha treatment is well  
known in the art and typically lasts four to six months.

15 The individual may also be treated with corticosteroids  
such as prednisolone.

Various further aspects and embodiments of the present  
invention will be apparent to those skilled in the art in  
20 view of the present disclosure. All documents referenced  
in this specification are incorporated herein by  
reference.

The skilled person will understand that the invention may  
25 be carried out with various combinations and sub-  
combinations of the features described above, and all  
these combinations and sub-combinations, whether or not  
specifically described or exemplified, are encompassed by  
the invention.

30 Certain aspects and embodiments of the invention will now  
be illustrated by way of example and with reference to  
the figures and tables described below.

Figure 1a shows an ELISA with serum samples from one responder at a range of peptide concentrations.

Figure 1b shows an ELISA with serum samples from one non-responder at a range of peptide concentrations.

Figure 2 shows ELISA data indicating the reproducibility of the test system.

Figure 3 shows results of analysis of pretreatment sera from three HBeAg<sup>+</sup> Polish children (one responder and two non-responders, solid lines) tested for IgG anti-preS1 (94-117) reactivity and compared with a pool (n=20) of healthy control individuals (dotted line)

Figure 4 shows the reactivity of pretreatment sera from one responder ( $\lambda$ ) and one non-responder ( $\nu$ ) HBeAg<sup>+</sup> Swedish adult patient.

Figure 5a shows the results of analysis of serum from one HBeAg<sup>+</sup> patient with chronic HBV- infection, who later spontaneously seroconverted to anti-HBe reactivity. Serum was incubated with incubation buffer instead of inhibitor (s dotted line), preS1(94-117, I dotted line) or preS1(21-32, n dotted line) before addition to preS1(94-117) coated ELISA plates. Data are given as OD values at 405nm

Figures 5b, 6a and 6b shows the results of analysis of serum of three HBeAg<sup>+</sup> patients with acute resolving HB-infection. Samples were incubated with incubation buffer instead of inhibitor (s dotted line), preS1(94-117, I dotted line) or preS1(21-32, n dotted line) before

addition to preS1(94-117) coated ELISA plates. Data are given as OD values at 405nm.

Figure 7 shows the results of analysis of serum from a HBeAg<sup>+</sup> chronic patient which was preincubated with preS1(94-117,  $\lambda$ ), the whole preS1(11-117,  $\sigma$ ) or the preS1 sequence(21-47) corresponding to the so called hepatocyte receptor (n).

Figure 8 shows the results of screening a cohort of 24 Chinese HBeAg<sup>+</sup> patients (Figure 8a), 17 Swedish HBeAg<sup>+</sup> patients (Figure 8b) and 68 healthy Swedish blood donors (Figure 8c). Background levels of healthy control sera are given to the left in the figures (open circles) and mean values are given. The OD<sub>405nm</sub> levels are plotted for each individual.

Figure 9 shows the results of screening cohorts of 37 HBeAg<sup>+</sup> Swedish adults, 36 HBeAg<sup>+</sup> Polish children and 43 HBeAg<sup>+</sup> Chinese adults. The IgG anti-preS1(94-117) reactivity are compared to that of control sera to the right of the figure.

Figure 10 shows the results of analysis of serum samples from one patient with acute resolving HBV- infection which were consecutively tested before and during acute infection. The X- axis gives the time schedule (days before and after onset of clinical symptoms). The solid line gives the IgG anti-preS1 (94-117) reactivity.

Figure 11 shows demonstrates the IgG anti-preS1(94-117) reactivity in serum samples consecutively collected during a 10 year time period during which the patient with

chronic HBV-infection spontaneously seroconvert from HBeAg to anti-HBe reactivity (after 5 years of follow-up) and after 10 years follow-up from HBsAg to anti-HBs reactivity.

5

Figure 12a shows Kinetic responses of IgG anti-preS1(94-117) reactivity for one responder patient treated with alpha-IFN (Wellferm) for 20 weeks. Serum samples were collected before, during and after treatment and analyzed for anti-preS1 reactivity (I solid line) and HBV-DNA (I dotted line) (Figure 12b). The background level in the ELISA plates with a pool (n=20) of healthy control sera are given by the dotted line (control 1-4).

15 Figure 12b shows the level of HBV-DNA in the pretreatment serum from the responder patient.

Figure 13a shows kinetic responses of IgG anti-preS1(94-117) reactivity for one non-responder (Figure 13a) patient treated with alpha-IFN (Wellferm) for 20 weeks. Serum samples were collected before, during and after treatment and analyzed for anti-preS1 reactivity (I solid line, OD 405nm) and HBV-DNA (I dotted line, pg/ml) (Figure 12b). The background level in the ELISA plates with a pool (n=20) of healthy control sera are given by the dotted line (control 1-4).

Figure 13b shows the level of HBV-DNA in the pretreatment serum from the non-responder patient.

30

Figure 14a shows kinetic responses of IgG anti-preS1(94-117) reactivity for one responder patient depicted before, during and after treatment with prednisone and

alpha-IFN. The solid line gives the OD values at 405nm for the anti-preS1 reactivity.

Figure 14b shows serum HBV levels for the responder patient. The dotted line gives the result of quantitative measurements of serum HBV-DNA (pg/ml).

Figure 15a shows kinetic responses of IgG anti-preS1(94-117) reactivity for one non-responder patient depicted before, during and after treatment with prednisone and alpha-IFN. The solid line gives the OD values at 405nm for the anti-preS1 reactivity.

Figure 15b shows kinetic responses of serum HBV-DNA levels. The dotted line gives the result of quantitative measurements of serum HBV-DNA (pg/ml).

Table 1 shows comparisons of the present methods for predicting response to IFN-alpha therapy compared to previously reported methods.

Table 2 shows the results of screening HBV patients using the present methods prior to IFN treatment.

Table 3 shows further results of screening HBV patients using the present methods prior to IFN treatment.

#### Examples

##### IgG anti-preS1#94-117 ELISA

##### Peptide:

A peptide consisting of the preS1#94-117 sequence of the HBV subtypes *adw*, *adw*<sub>2</sub> and two out of three described *adr* subtypes (i.e. PASTNRQSGRQPTPISPPLRDSHP) were obtained from Sigma Genosys, London Road, Cambridge, UK. The

peptide was supplied lyophilized, resuspended in sterile distilled water and kept at  $-20^{\circ}\text{C}$ . The purity was  $> 95\%$  by HPLC.

5 *ELISA plates:*

Microtiter plates; Immunolon 2, flat bottom plates Catalog No. 011-010-3455 were obtained from Dynatech Laboratories Inc., Chantilly, Virginia, USA through the Swedish agency In vitro Sweden AB, Stockholm.

10

*Coating buffer:*

0.05M sodium carbonate buffer, pH 9.6 [1.59g  $\text{Na}_2\text{CO}_3$  (Catalogue No S-2127, min99%, Sigma-Aldrich) and 2.93g  $\text{NaHCO}_3$  (Catalogue No S-8875 min 99.5%, Sigma-Aldrich) to 1000ml with distilled water] was used as coating buffer.

15

The peptide was diluted to final concentrations of 500, 1000 and 2000 ng/ml. In another test series, the final concentrations were 800, 1600 and 3200ng/ml. For screening procedures, a final concentration of 2000ng/ml was used throughout the studies. Fifty  $\mu\text{l}$  was added/well.

20

*Coating procedure:*

For optimal coating, the plates were charged by incubation at  $40^{\circ}\text{C}$  for 4 hours and thereafter stored in refrigerator at  $4^{\circ}\text{C}$  overnight before use.

25

Throughout the screening procedure described herein, plates were stored overnight at  $-4^{\circ}\text{C}$  before used in the assay (Figure 1A).

30

*Washing of ELISA plates:*

After each of the steps: 1) coating of plates, 2) incubation with patient- or control-sera, 3) incubation with conjugate, the plates were washed with 0.05M NaCl

(Catalogue No S-7653, SigmaUltra min 99.5%, Sigma-Aldrich) with 0.05% Tween.

Plates were washed three times by hand (e.g. without automated washing) with incubations of 5-10 minutes each time.

*Incubation with patient sera;*

Patient sera were diluted 1/125 for screening procedures or in two-step dilutions from 1/125 to 1/16 000 for titration experiments in 0.05M phosphate-buffered saline (PBS) containing 0.05% Tween 20 (Polyoxyethylenesorbitan Monolaurate, Catalogue No P-1379, Sigma-Aldrich Sweden AB) and 1% Foetal bovine serum (FBS, heat-inactivated 56°C 90 minutes) (catalogue No 10106-151 Gibco BRL, Life Technologies). Diluted sera (50µl/well) were incubated at plates 4°C overnight. (Shorter incubation time periods was not analyzed for during this set of experiments). The protein content in the dilution reagent is of importance and 1% FBS have earlier been found to be optimal during this type of "site-specific" ELISA systems.

*Incubation with conjugate:*

Anti-human IgG conjugate: Affinity isolated antibodies to human IgG (gamma-chains specific) from goat labelled with alkaline phosphatase was used (Catalogue No A-3187, Sigma Aldrich).

The conjugate was diluted 1/1000 in PBS containing 0.05% Tween and 1% FBS and incubated on plates at 4°C overnight.

*Substrate:*

p-nitrophenyl phosphate in diethanolamine HCl was used as substrate: Sigma 104 phosphatase substrate (p-Nitrophenyl

- phosphate, disodium, hexahydrate) 5mg tablets was dissolved in 5ml diethanolamine HCl, pH 9.8 [97ml diethanolamine (Catalogue No D-8885 min 98%), 101mg  $\text{MgCl}_2 \cdot 6\text{H}_2\text{O}$  (Catalogue No M-0250, Magnesium Chloride, Hexahydrate, Sigma-Aldrich) and approx. 160ml 1M HCl (Hydrochloric acid, 1mol/l, Riedel-de Haén, 35328, Sigma-Aldrich 01780) in 1000ml distilled water to get pH 9.8].

*Reading of plates:*

- 10 The optical density (OD) value at 405nm was measured in a TITERTEK Multiskan Plus Photometer (Flow Laboratories, Edinburgh, Scotland) after incubations for different time periods varying between 5-60 minutes. At optimal conditions plates was read after 20-30 minutes of  
15 incubation.

*Normal (N) values:*

Sera from twenty healthy blood donors were pooled and used as control sera (n=20).

- 20 For screening purposes of unknown patient sera it is important that the different control sera tested negative for IgG, IgM and IgA anti- hepatitis (A, B, C, D and E) markers. The control sera were tested in commercially  
25 available test systems from Abbott Laboratories. Sera with reactivity within the grey zone 10-20%  $\pm$  the cut-off value were avoided.

- During these assay conditions the mean OD 405 value for  
30 control (n=20) sera  $\pm$  5 SD was equivalent to sample (S) over normal (N) values  $(S/N) \geq 2.5$ .



*Patient sera with positive reactivity:*

For screening procedures patient and control sera were diluted 1/125 and assayed for reactivity. S/N values  $\geq$  2.5 were considered positive.

5

Titers of sera: Both patient- and control- sera were diluted from 1/125 to 1/16 000 and assayed for reactivity. The end-point for positive reactivity could thereafter be found.

10

*Inhibition experiments:*

Equal volumes of diluted (PBS-Tween-1%FBS) patient sera and inhibitor (PBS-Tween-1% FBS) were incubated for 4 hours at 4°C and thereafter transferred to coated ELISA plates, followed by the procedure described above.

15

Inhibitory reagents used: preS1#94-117, preS1#21-32, preS1#11-117, preS1#21-47.

*Statistics:*

20

The non-parametric Mann-Whitney U test was employed to compare data between groups of patients.

The Chi-squared test was used to compare number of reactive individuals in different group of patients when the individuals in the groups were  $\geq$  5.

25

The Fischer's exact test was used when the patient groups were smaller than 5.

Optimal concentration of the peptide protein for charge of the solid phase (eg ELISA plates).

30

The solid phase (i.e. ELISA plates) were charged with 500, 1000 or 2000 ng peptide/ml. Serum samples from one responder (Figure 1a) and one non-responder (Figure 1b)

HBeAg- reactive patient (solid line) were compared with a pool (n=20) of "healthy" control sera (dotted lines).

Sera were diluted 1/125 and analysed for IgG anti-preS1 (94-117) reactivity. OD values at 405 nm are given.

5

For the responder patient (Swedish adult), the serum samples were collected before (-1 week), during (4, 6 and 18 weeks) and after (4, 9 and 18 months) treatment with alpha-IFN (Wellferm) for 20 weeks (Figure 1a).

10

For the non-responder patient (Swedish adult), the serum samples were collected before (time 0), during (4, 10 and 14 weeks) and after (18 months) of treatment (Figure 1b).

The responder patient had an IgG anti-preS1 (94-117)

15 reactive pretreatment serum, while the pretreatment serum from the non-responder patient lacked detectable levels of anti-preS1 antibodies.

The 200ng/ml coat of plates gave the lowest background  
20 level. A charge of the solid phase of 2000ng/ml of the preS1 (94-117) peptide was thereafter used throughout the study for screening procedures.

#### Reproducibility

The reproducibility of the test system is shown in Figure  
25 2. The reactivity is given for the responder patient discussed above when the same serum samples were tested one month apart.

#### The Curve Profile of IgG Anti-preS1 (94-117) Reactive Patient Sera in the Assay System.

30 Pretreatment sera from three HBeAg<sup>+</sup> Polish children (one responder and two non-responders, solid lines) were tested for IgG anti-preS1 (94-117) reactivity and compared with a pool (n=20) of healthy control

individuals (dotted line) (Figure 3) Sera were diluted two-stepwise from 1/125 to 1/16 000 and data presented as OD values at 405nm).

- 5 The pretreatment responder patient serum (●) contained high titers (end point 4000) of IgG anti-preS1(94-117) compared to the two pretreatment sera from non-responder patients (▲ and ■) which were negative.
- 10 Figure 4 demonstrates the reactivity of pretreatment sera from one responder (●) and one non-responder (■) HBeAg<sup>+</sup> Swedish adult patient.

The pretreatment serum from the responder patient was  
15 positive with a high titer (2000) of IgG anti-preS1(94-117) antibodies, while the pretreatment serum from the non-responder lacked detectable levels of antibodies.

Specificity of the IgG anti-preS1(94-117) ELISA.

Inhibition of IgG anti-preS1(94-117) reactivity.

- 20 Serum from one HBeAg<sup>+</sup> patient (Figure 5a) with chronic HBV-infection, who later spontaneously seroconverted to anti-HBe reactivity and three HBeAg<sup>+</sup> patients with acute resolving HB-infection (Figures 5b, 6a and 6b) were incubated with incubation buffer instead of inhibitor (▲ dotted line), preS1(94-117) (● solid line) or preS1(21-32) (■ dotted line) before addition to preS1(94-117) coated ELISA plates. Data are given as OD values at  
25 405nm.

- 30 The soluble preS1(94-117) peptide inhibited the IgG anti-preS1(94-117) reactivity to 100%, while the preS1 peptide (21-32) from the N-terminal part of preS1 did not.

Serum from a HBeAg+ chronic patient was preincubated with preS1(94-117, ●), the whole preS1(11-117, ▲) or the preS1 sequence(21-47, ■) corresponding to the so called  
 5 hepatocyte receptor (n) (Figure 7).

The soluble preS1(94-117) peptide inhibited the IgG anti-preS1(94-117) reactivity to 100%. While the irrelevant preS1 peptides did not.

10 Sensitivity of the IgG anti-preS1(94-117) ELISA at different follow-up times

Twelve out of 13 (92%) HBeAg+ patients responded to treatment with alpha-IFN alone or in combination with prednisone when followed 12 (Fu 12) up to 18 (Fu 18)  
 15 months after end of treatment (Table 2). Response was judged by the elimination of viral replication as assessed by quantitative measurements of serum HBV-DNA and/or seroconversion from HBeAg to anti-HBe reactivity.

20 The responder patient who is classified in the Table 2 as negative had a borderline reactivity and was positive in some, but negative in other experiments. The reactivity pattern of this patient may be retested with more serum samples.

25 In contrast all non-responder patients (0/9, 0%) lacked detectable levels of IgG anti-preS1(94-117) (Table 3). The difference in IgG anti-preS1(94-117) reactivity between responder and non-responder patients is  
 30 significant ( $p < 0.0005$ ).

For another set of HBeAg+ patients followed 1, 2, 3 or 6 months after treatment (Tables 2 and 3) 6/7 (86%)

responder patients compared to 0/13 (0%) non-responder patients ( $p < 0.0005$ ) had pretreatment samples with detectable levels of IgG anti-preS1(94-117).

- 5 The IgM anti-preS1(94-117) reactivity in pretreatment did not differ significantly between responder and non-responder patients (Tables 2 and 3).

#### Comparison with Other Predictive Markers.

- 10 Pretreatment samples from responder compared to non-responder patients were also analysed for content of IgM anti-HBc (Sample/Cut-off, S/CO), transaminases (ALT,  $\mu\text{kat/L}$ ), serum HBV-DNA (pg/ml) and histology (CPH or CAH) (Tables 2 and 3). These parameters have earlier been discussed in the context of search for predictive  
15 markers. For the patients tested in this study, no significant differences were found between the two groups of patients.

- 20 IgM and IgG antibodies with specificity for the first or the second part of the hepatocyte receptor; preS1(12-32) or preS1 (32-47), did not differ significantly between responder and non-responder patients (Tables 2 and 3).

- 25 The IgG anti-preS1(94-117) reactivity in sera from a cohort of HBeAg reactive sera from patients (Swedish, Polish and Chinese) with chronic HBV-infection.

- For screening, patient and control seras were diluted 1/125. Results from three different experiments are depicted in Figure 8 a-c. Background levels of healthy  
30 control sera are given to the left in the figures (open circles) and mean values are given.

The OD405nm levels are plotted for each individual in a cohort of 24 Chinese HBeAg+ patients (Figure 8a), 17 Swedish HBeAg+ patients (Figure 8b) and 68 healthy Swedish blood donors (Figure 8c).

5

In another set of experiments (Figure 9) the OD values at 405nm are plotted for each individual in cohorts of 37 HBeAg+ Swedish adults, 36 HBeAg+ Polish children and 43 HBeAg+ Chinese adults. The IgG anti-preS1(94-117)

10 reactivity are compared to that of control sera to the right of the figure.

Sample (S) over normal (N) values  $> 2.5$  are judged as the cut-off value for positive reactivity. It equals a mean  
15 control value  $\pm 5-6SD$ .

A cohort of HBeAg+ patients (22-25%) have detectable levels of IgG anti-preS1(94-117) in sera. The frequency of IgG anti-preS1(94-117) reactive sera from HBeAg+  
20 patients were the same, irrespective of ethnical origin (eg Chinese or Swedish).

Kinetic response of IgG anti-preS1(94-117) reactivity in sera during acute HBV-infection.

Serum samples from one patient with acute resolving HBV-  
25 infection were consecutively tested before and during acute infection (Figure 10). The X- axis gives the time schedule (days before and after onset of clinical symptoms). The solid line gives the IgG anti-preS1 (94-117) reactivity. Serum samples were negative for IgG  
30 anti-preS1(94-117) before but reactive after onset of clinical symptoms. The IgG anti-preS1 (94-117) reactivity peaked at the time for HBeAg/anti-HBe seroconversion (36

days) but declined at the time for HBsAg/anti-HBs seroconversion (162 days).

The dotted line gives the background values in the plates with a pool (n=20) of healthy control sera.

Kinetic response of IgG anti-preS1 (94-117) reactivity in a HBeAg chronic patient who spontaneously seroconvert to anti-HBe and later to anti-HBs.

Figure 11 demonstrates the IgG anti-preS1(94-117) reactivity in serum samples consecutively collected during a 10 year time period during which the patient with chronic HBV-infection spontaneously seroconverted from HBeAg to anti-HBe reactivity (after 5 years of follow-up; month/year 4/83) and after 10 years follow-up (month/year 1/88) from HBsAg to anti-HBs reactivity. The serum IgG anti-preS1(94-117) reactivity fluctuates during HBe- antigenimia, reaching peak levels after the seroconversion to anti-Hbe and declining during the time for seroconversion to anti-HBs reactivity.

Kinetic responses of IgG anti-preS1(94-117) reactivity during treatment with alpha-IFN in responder compared to non-responder patients.

Kinetic responses of IgG anti-preS1(94-117) reactivity for one responder (Figure 12a) and one non-responder (Figure 13a) patient treated with alpha-IFN (Wellferm) for 20 weeks. Serum samples were collected before, during and after treatment and analyzed for anti-preS1 reactivity (solid line) (Figures 12a and 13a) and HBV-DNA (dotted line, pg/ml) (Figures 12b and 13b). The background level in the ELISA plates with a pool (n=20)

of healthy control sera are given by the dotted line (control 1-4).

5 The pretreatment serum from the responder patient contained anti-preS1 antibodies and HBV-DNA (Figures 12a and 12b), while the pretreatment serum from the non-responder patient had high levels of HBV-DNA but lacked detectable levels of IgG anti-preS1(94-117) (Figures 13a and 13b).

10

The presence of serum antibodies with specificity for the N-terminal part of preS1 is dynamic and is fluctuating during the treatment schedule. For the responder patient, the reactivity reached a peak at the time for  
15 seroconversion from HBeAg to anti-HBe reactivity.

Kinetic responses of IgG anti-preS1 (94-117) reactivity during combined prednisone, alpha-IFN treatment.

Kinetic responses of IgG anti-preS1(94-117) reactivity  
20 for one responder (Figure 14a) and one non-responder (Figure 15a) patient are depicted before, during and after treatment with prednisone and alpha-IFN. The solid line gives the OD values at 405nm for the anti-preS1 reactivity (Figures 14a and 15a) and the dotted line the  
25 result of quantitative measurements of serum HBV-DNA (pg/ml). (Figures 14b and 15b). Positive pretreatment levels of anti-preS1 for the responder patient (Figure 14a).

30 The predictive marker is valid both for alpha-IFN treatment with or without combined treatment with prednisolone.



### Comparison with Known Predictive Markers

Predicted response to IFN-alpha therapy based on pretreatment data has previously been studied by the use of various statistical models.

5.

Lau et al, 1998 *Journal of Viral Hepatitis* 5: 105-114 gave the arbitrary prediction to be 33% responders and 67% non-responders, see Table 1. By the use of a two-stage logistic model with pretreatment variables (sex, hepatic fibrosis, ALT levels) they increased the number of responders from 33% to 61% (e.g. the sensitivity and non-responders from 67% to 76% (e.g. the specificity). By Smiles logistic regression the numbers of responders to non-responders increased to 77% and 87%, respectively.

15.

Brook et al, 1989 *Hepatology* 10: 761-763 increased the sensitivity from 33 to 77% and the specificity from 67 to 79% by the use of pretreatment variables AST levels and history of acute hepatitis.

20

Perillo et al, 1993 *Hepatology* 18: 1306-1312 used stepwise Cox regression analysis with pretreatment variables HBeAg and ALT levels. The sensitivity and the specificity was raised to 81% and 46% respectively.

25

Lindh et al and Söderström et al used the pretreatment variable HBV-DNA (<500 million copies/ml and 160 million copies/ml, respectively). The sensitivity was 51% and 67%, respectively and the specificity 74% and 89%, respectively.

30

The first group (Lindh et al) treated adults, while the latter group (Söderström, et al) treated children with a combined regime

The data obtained from the non-invasive assay described herein shows that the sensitivity was raised from 33% to

92% and the specificity from 67% to 100%, with a follow-up 12-18 months (Table 1 and 2).

		<u>Responders</u>	<u>Non-responders</u>
	Arbitrary prediction	33%	67%
5	Lau et al, 1998	<u>Sensitivity</u>	<u>Specificity</u>
	The two-stage logistic model using Pretreatment variables (sex, hepatic Fibrosis and ALT levels)	61%	76%
10	Smiles logistic regression Incorporates interactions between the parameters	77%	87%
15	Brook et al, 1989 Pretreatment variables (AST levels and history of acute hepatitis)	77%	79%
20	Perillo et al, 1993 Stepwise Cox regression analysis (pretreatment variables HBeAg concentrations and ALT levels)	81%	46%
25	Lindh et al, 2001 (combined therapy) Pretreatment variable HBV-DNA (< 500 million copies/ml)	51%	74%
30	Söderström et al, 2003 (combined therapy, children) Pretreatment variable HBV-DNA (160 million copies/ml)	67%	89%
35	Hellström and Sylvan (New data) Presence of IgG anti-preS1(94-117) antibodies in pretreatment sera) Follow-up time 12-18 months	92%	100%
40	Lau et al ( <i>Journal of Viral Hepatitis</i> 5:105-114, 1998)		
	Brook et al ( <i>Hepatology</i> 10: 761-763, 1989)		
45	Perillo et al ( <i>Hepatology</i> 18: 1306-1312, 1993)		
	Lindh et al ( <i>Journal of Viral Hepatitis</i> 8: 349-357, 2001)		
	Söderström et al, 2003 ( <i>Thesis</i> )		

Table 1

## RESPONDER PATIENTS

## Pretreatment anti-Presl markers

IgG anti-presl      IgM anti-p

5

Oresl

Name	Age	Sex	Treatm	Follow-up	21-32	32-47	94-117	21-32	32-47	94-117	IgM a-HBc ALT	HBV-DNA	Hist
2442	Sw adult	M	IFN	Fu 18	neg	pos	pos	pos	pos	pos	2.3	58	1981
2461	Sw adult	M	IFN	Fu 18	neg	neg	pos	pos	pos	pos	0.6	33	2690
2421	Sw adult	M	IFN	Fu 18	pos	pos	pos	neg	neg	neg	1.5	66	691
2482*	Sw adult	M	IFN	Fu 18	neg	neg	neg*	neg	neg	neg	2.2	54	5353
Kanafek	Po 2 1/4	M	IFN	Fu 18	pos	pos	pos	pos	pos	pos	0.6		610
alpha-10	Ch 35	F	ST/IFN	Fu 18	pos	pos	pos	pos	pos	pos	1.5		77
Dziewa	Po 5 1/2	F	ST/IFN	Fu 12	pos	pos	pos	pos	pos	pos	4.2		78
337	Po 12 1/2	F	IFN	Fu 12	pos	pos	pos	pos	pos	pos	1.4	220	
3211	Po 4	M	IFN	Fu 12	pos	pos	pos	neg	pos	neg	0.5	233	
1950	Po 5 5/12	F	IFN	Fu 12	pos	pos	pos	neg	neg	neg	0.4	51	
2090	Po 5	M	IFN	Fu 12	pos	neg	pos	pos	pos	pos	0.3	145	
1017	Po 4	M	IFN	Fu 12	pos	neg	pos	pos	pos	pos	0.3	34	
2324	Po 2	M	IFN	Fu 12	pos	pos	pos	pos	pos	pos	1.9	450	
n=13					10 pos	9 pos	12 pos	9 pos	10 pos	9 pos	1.4±0.3	134±42	1640±721
					77%	69%	92%	69%	77%	69%			
					a)	b)	c)	d)	e)	f)	g)	h)	i)

\* pos sometimes/neg sometimes.

Table 2a

25

NON-RESPONDER PATIENTS

Pretreatment anti-Pres1 markers

	Name	Age	Sex	Treatm	Follow-up	IgG anti-pres1			IgM anti-pres1			HBV-DNA	Hist		
						21-32	32-47	94-117	21-32	32-47	94-117				
5	2462	Sw adult	M	IFN	Fu 18	neg	pos	neg	neg	neg	neg	5.9	57	3064	
	2443	Sw adult	M	IFN	Fu 18	neg	pos	neg	neg	neg	neg	2.1	57	13,880	
	Suchan	Po 4 1/12	M	IFN	Fu 18	pos	pos	neg	neg	neg	neg	1.9		160	CAH
	Dunczyk	Po 2 1/6	M	ST/IFN	Fu 12	pos	pos	neg	pos	neg	neg	0.5		780	CPH
	Zyfert	Po 5 2/3	M	ST/IFN	Fu 12	neg	neg	neg	pos	pos	pos	0.8		550	CAH
10	Gorbacz	Po 6 1/2	M	ST/IFN	Fu 12	pos	pos	neg	neg	neg	neg	0.6			CAH
	71	Po 1 1/3	M	IFN	Fu 12	pos	neg	neg	pos	pos	neg	0.3			CAH
	831	Po 13 5/12	F	IFN	Fu 12	neg	neg	neg	neg	neg	neg	0.4	136		CAH
	alpha-6	Ch 33	M	ST/IFN	Fu 12	neg	neg	neg	neg	neg	neg	0.5	136		CAH
	n=9					4 pos	5 pos	0 pos	3 pos	2 pos	1 pos	1.4±0.6	97±23	3686±2598	6 CAH
15						44%	56%	0%	33%	22%	11%				86%
						a)	b)	c)	d)	e)	f)	g)	h)	i)	k)
						NS	NS		NS	NS	NS	NS	NS	NS	NS
						p< 0.0005									
						Table 2b									

Table 3 RESPONDER PATIENTS

Pretreatment anti-Pres1 markers

Name	Age	Sex	Treatm	Follow-up	IgG anti-pres1				IgM anti-pres1				IgM a-HBcALT	HBV-DNA	Hist
					21-32	32-47	94-117	21-32	32-47	94-117	21-32	32-47	94-117		
Kaminska	Po 1 y 9/12	F	IFN	Fu 6	pos	pos	pos	pos	pos	pos	neg	pos	pos	2.6	CPH
Walasiak	Po 12 1/12	M	IFN	Fu 6	pos	pos	pos	pos	pos	pos	neg	pos	pos	0.9	CAH
146	Po 12	M	IFN	Fu 6	neg	neg	pos	pos	neg	neg	neg	pos	pos	0.4	CPH
2337	Po 2	M	IFN	Fu 6	pos	pos	pos	pos	pos	pos	pos	pos	neg	1.9	CAH
A3	Ch 40	F	IFN	Fu 6	pos	neg	pos	pos	pos	pos	pos	pos	pos	1.1	CAH
Zlotek*	Po 4 1/2	M	ST/IFN	Fu 6	pos	pos	neg*	neg	neg	neg	neg	neg	neg	1.1	CAH
B1	Ch 36	M	IFN	Fu 3	pos	neg	pos	pos	neg	pos	neg	pos	neg	0.5	CAH
n=7					6 pos	4 pos	6 pos	2 pos	5 pos	4 pos	2 pos	5 pos	4 pos	1.2±0.3	5 CAH
					86%	57%	86%	29%	71%	57%	29%	71%	57%		71%

15 \*difficult to judge whether this patient is a R or NR

Table 3a

# NON-RESPONDER PATIENTS

## Pretreatment anti-Pres1 markers

Name	Age	Sex	Treatm	Follow-up	IgG anti-pres1					IgM anti-pres1					HBV-DNA	Hist
					21-32	32-47	47-94	94-117	117-210	21-32	32-47	47-94	94-117	117-210		
Fir-lag	Po 8	M	ST/IFN	Fu 6	pos	pos	neg	neg	neg	neg	neg	neg	neg	neg	0.3	CPH
alpha-9	Ch 37	M	ST/IFN	Fu 6	neg	neg	neg	neg	neg	neg	neg	neg	neg	neg	0.8	CAH
698	Po 2 5/6	M	IFN	Fu 6	pos	pos	pos	neg	neg	neg	neg	neg	neg	neg	0.2	CAH
960	Po 3 4/12	F	IFN	Fu 6	neg	neg	neg	neg	neg	pos	pos	pos	pos	pos	0.2	CAH
550	Po 1y 8/12	M	IFN	Fu 6	neg	neg	neg	neg	neg	neg	neg	neg	neg	neg	0.3	CAH
4083	Po 2	M	IFN	Fu 6	neg	pos	pos	neg	neg	pos	pos	pos	pos	pos	0.3	CAH
2295	Po 4 5/12	M	IFN	Fu 3	neg	pos	pos	neg	neg	neg	neg	neg	neg	neg	1.1	CAH
4168	Po 2	F	IFN	Fu 3	neg	neg	neg	neg	neg	pos	pos	neg	neg	neg	0.5	CPH
3572	Po 6y 4mo	M	IFN	Fu 3	neg	neg	neg	neg	neg	pos	pos	neg	neg	neg	0.5	CPH
535	Po 8y 3mo	F	IFN	Fu 3	neg	neg	neg	neg	neg	pos	pos	neg	pos	pos	0.4	CAH
A11	Ch 39	M	IFN	Fu 2	pos	pos	neg	neg	neg	neg	neg	neg	pos	pos	1.7	CAH
A4	Ch 38	M	IFN	Fu 1	pos	neg	neg	neg	neg	neg	neg	neg	neg	neg	6.1	CAH
B4	Ch 28	M	IFN	Fu 1	pos	pos	neg	neg	neg	neg	neg	neg	neg	neg	40	CAH
n=13					5 pos	6 pos	0 pos	4 pos	2 pos	4 pos	31%	15%	31%	1.0±0.5	100±33	4892±4708
20					38%	46%	0%	31%	15%	31%	g)	h)	i)	77%	10	CAH
					a)	b)	c)	d)	e)	f)	g)	h)	i)	k)		
					NS	NS	NS	NS	NS	NS	NS	NS	NS	NS		

p<0.0005

Table 3b

## Claims:

- 5 1. A method of predicting whether an individual having hepatitis B virus (HBV) infection will respond to interferon (IFN) treatment; the method comprising;  
determining the presence or absence of antibodies  
reactive with a preS1(94-117) peptide in a sample  
10 obtained from the individual,  
the presence of said antibodies in said sample being  
indicative that said individual will respond to said  
treatment.
- 15 2. A method according to claim 1 comprising detecting  
the presence of said antibodies in said sample and  
thereby determining that the individual will respond to  
IFN treatment
- 20 3. A method according to claim 1 comprising detecting  
the absence of said antibodies in said sample and thereby  
determining that the individual will not respond to IFN  
treatment
- 25 4. A method according to any one of the preceding  
claims wherein the individual has chronic HBV infection.
5. A method according to any one of the preceding  
claims wherein the individual is HBeAg positive.
- 30 6. A method according to any one of claims 1 to 4  
wherein the individual is HBeAg negative.



7. A method according to any one of the preceding claims wherein the antibodies are IgG or IgM antibodies.

8. A method according to any one of the preceding  
5 claims wherein the sample is a blood, serum or plasma sample.

9. A method according to any one of the preceding claims comprising;  
10 contacting the sample with a preS1(94-117) peptide and;  
determining binding of said antibodies to said peptide.

15 10. A method according to claim 9 wherein the peptide comprises a detectable label.

11. A method according to claim 9 wherein said peptide is immobilised.

20 12. A method according to any one of claims 9 to 11 wherein said binding is detected with a labelled secondary antibody.

25 13. A kit for use in predicting whether an individual having hepatitis B will respond to interferon (IFN) treatment, the kit comprising;  
a preS1(94-117) peptide.

30 14. A kit according to claim 13 wherein said peptide is immobilised on a solid support.

15. A kit according to claim 14 wherein the solid support is a microtitre plate.

16. A kit according to any one of claims 13 to 15 further comprising a labelled secondary antibody which binds to human antibodies.

5

17. A kit according to any one of claims 13-16 further comprising reagents for detecting the binding of the labelled secondary antibody

10 18. A kit according to any one of claims 13-17 further comprising wash buffers.

19. A kit according to any one of claims 13-18 further comprising sample-handling containers.

15

20. A method of treating a hepatitis B infection in an individual comprising;

identifying the individual as responsive to  
interferon (IFN) treatment using a method according to  
20 any one of claims 1 to 12, and;  
administering IFN to said individual.

21. A method according to claim 20 wherein the IFN is alpha-IFN.

25

22. A method according to claim 20 or claim 21 wherein corticosteroid is administered to the individual.

23. A method of predicting whether an individual having  
30 hepatitis B virus (HBV) infection will respond to  
interferon (IFN) treatment which is substantially as  
described herein, with reference to the accompanying  
table and figures.


ABSTRACTMethods and Means Relating to Hepatitis B Infection

5

The present inventors have discovered that the presence of antibodies reactive with residues 94-117 of the PreS1 component of the hepatitis B surface antigen (HBsAg) in an individual with HBV infection correlates closely with the effectiveness of interferon (IFN) in treating the individual. Methods and means based on this finding are provided herein.

10

15



5

Figure 1a

10




Figure 1b




Figure 2




Figure 3





Figure 4





5

Figure 5A

10




Figure 5B




Figure 6A





Figure 6B



5

Figure 7

10




Figure 8

Fig 9




Figure 9




Figure 10






Figure 11




Figure 12A




Figure 12B




Figure 13A




Figure 13B




Figure 14A





Figure 14B



5

Figure 15A






Figure 15B

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/EP04/011958

International filing date: 22 October 2004 (22.10.2004)

Document type: Certified copy of priority document

Document details: Country/Office: GB  
Number: 0326416.5  
Filing date: 12 November 2003 (12.11.2003)

Date of receipt at the International Bureau: 17 February 2005 (17.02.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**